MARKET

NURO

NURO

Neurometrix Inc
NASDAQ
4.440
+0.030
+0.68%
After Hours: 4.640 +0.2 +4.50% 19:32 04/26 EDT
OPEN
4.330
PREV CLOSE
4.410
HIGH
4.640
LOW
4.300
VOLUME
32.12K
TURNOVER
0
52 WEEK HIGH
11.68
52 WEEK LOW
2.700
MARKET CAP
8.82M
P/E (TTM)
-0.7085
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NURO last week (0415-0419)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. NKGen Biotech stock increased by 19.76% and Adlai Nortye stock moved upwards by 16.33%. Other losers include SeaStar Medical Holding and iSpecimen.
Benzinga · 04/19 16:31
NeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement Steps
NASDAQ · 04/19 15:07
Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers
Seeking Alpha · 04/19 14:00
NeuroMetrix names new independent director, terminates equity program; shares up
Seeking Alpha · 04/19 13:10
NeuroMetrix Board Appointment and Equity Program Termination
TipRanks · 04/19 12:22
NEUROMETRIX INC - APPROVED APPOINTMENT OF JOSHUA S. HOROWITZ AS A NEW INDEPENDENT DIRECTOR WITH A 1-YEAR TERM
Reuters · 04/19 12:00
Press Release: NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value Joshua S. Horowitz joins Board of Directors at-the-market equity facility terminated. The Board has approved the appointment of Joshua Horowitz as a new independent director with a 1-year term. The Company has also terminated its at- the- market equity facility with Echo Lake Capital.
Dow Jones · 04/19 12:00
More
About NURO
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Webull offers Neurometrix Inc stock information, including NASDAQ: NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.